ImmuCell Corporation — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$8M↓-1.6%
2025-09-30$6M↓-8.4%$-140K↑+80.1%0.4%
2025-06-30$6M↑+17.8%$502K↑+132.8%8.8%
2025-03-31$8M↑+11.2%$1M↑+430.5%13.9%
2024-12-31$8M↑+52.1%
2024-09-30$6M↑+11.4%$-702K↑+25.4%-9.6%
2024-06-30$5M↑+54.9%$-2M↓-11.0%-25.3%
2024-03-31$7M↑+110.6%$-438K↑+81.1%-4.1%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$8M
↓-1.6% -$125K YoY
Net Income
$1M
↑+10.9% +$131K YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 63 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+1.6pts
38.2%
Operating Margin↑+9.9pts
0.4%
Net Margin↑+9.1pts
-2.5%

Go deeper